stocks logo

SAGE

SAGE Therapeutics Inc
$
0.000
-8.68(-100.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
643.35M
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
60.18M
EV
179.40M
EV/OCF(TTM)
--
P/S(TTM)
16.05
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
24.63M
+107.47%
-0.870
-43.14%
27.48M
+114.4%
-0.857
-28.43%
26.70M
+89.85%
-1.040
+4.26%
Estimates Revision
The market is revising Upward the revenue expectations for Sage Therapeutics, Inc. (SAGE) for FY2025, with the revenue forecasts being adjusted by 17.29% over the past three months. During the same period, the stock price has changed by 26.53%.
Revenue Estimates for FY2025
Revise Upward
up Image
+17.29%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.16%
In Past 3 Month
Stock Price
Go Up
up Image
+26.53%
In Past 3 Month
15 Analyst Rating
up Image0
Wall Street analysts forecast SAGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SAGE is 8.66 USD with a low forecast of 5.00 USD and a high forecast of 12.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
14 Hold
1 Sell
Hold
up Image0
Current: 0
sliders
Low
5.00
Averages
8.66
High
12.00
Scotiabank
George Farmer
Outperform -> Sector Perform
downgrade
$9.20
2025-07-07
Reason
Scotiabank analyst George Farmer downgraded Sage Therapeutics (SAGE) to Sector Perform from Outperform with a $9.20 price target. Supernus Pharmaceuticals (SUPN) has announced an agreement to acquire Sage through a tender offer for $8.50 per share in cash, payable at closing, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash, for total consideration of $12.00 per share in cash.
JPMorgan
Anupam Rama
Neutral
downgrade
$11
2025-06-22
Reason
JPMorgan analyst Anupam Rama lowered the firm's price target on Sage Therapeutics to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut.
Baird
Joel Beatty
Neutral
maintain
$7 -> $9
2025-06-21
Reason
Baird analyst Joel Beatty raised the firm's price target on Sage Therapeutics to $9 from $7 and keeps a Neutral rating on the shares. The firm updated its target to reflect its proposed acquisition price.
Piper Sandler
Overweight -> Neutral
downgrade
$9
2025-06-18
Reason
Piper Sandler downgraded Sage Therapeutics to Neutral from Overweight with a price target of $8.50, down from $9, after the company entered into an agreement for Supernus to acquire it through a tender offer for $8.50 per share in cash plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash.
BofA
Underperform -> No Rating
downgrade
$12
2025-06-18
Reason
BofA moved to No Rating from Underperform on Sage Therapeutics (SAGE) after the company announced a definitive agreement to be acquired by Supernus Pharmaceuticals (SUPN) for a total up to $12 per share. Sage shares are no longer trading on fundamentals given the deal announcement, the analyst tells investors.
Wedbush
Laura Chico
Hold
Reiterates
$6
2025-02-12
Reason

Valuation Metrics

The current forward P/E ratio for SAGE Therapeutics Inc (SAGE.O) is -2.49, compared to its 5-year average forward P/E of -4.94. For a more detailed relative valuation and DCF analysis to assess SAGE Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.94
Current PE
-2.49
Overvalued PE
-1.40
Undervalued PE
-8.47

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.38
Current EV/EBITDA
-0.59
Overvalued EV/EBITDA
9.56
Undervalued EV/EBITDA
-8.81

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
115.23
Current PS
5.86
Overvalued PS
290.01
Undervalued PS
-59.55

Financials

Annual
Quarterly
FY2025Q2
YoY :
+265.84%
31.66M
Total Revenue
FY2025Q2
YoY :
-51.25%
-54.25M
Operating Profit
FY2025Q2
YoY :
-51.73%
-49.65M
Net Income after Tax
FY2025Q2
YoY :
-53.53%
-0.79
EPS - Diluted
FY2025Q2
YoY :
-27.04%
-58.69M
Free Cash Flow
FY2025Q2
YoY :
+19.42%
100.00
Gross Profit Margin - %
FY2025Q2
YoY :
+6.88%
-410.93
FCF Margin - %
FY2025Q2
YoY :
-86.80%
-156.83
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
2.6M
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
1
443.0K
Volume
Months
3-6
1
2.0M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

SAGE News & Events

Events Timeline

2025-07-30 (ET)
2025-07-30
16:17:48
Sage Therapeutics reports Q2 EPS (79c), consensus (94c)
select
2025-07-28 (ET)
2025-07-28
08:28:11
Supernus announces expiration of HSR waiting period for Sage Therapeutics
select
2025-07-01 (ET)
2025-07-01
09:29:16
Sage Therapeutics cutting over 330 jobs, Boston Globe reports
select
link
Sign Up For More Events

News

8.5
07-31Newsfilter
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
8.5
07-28Newsfilter
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
9.0
07-25NASDAQ.COM
Biogen's ZURZUVAE Wins EMA Panel Backing For Postpartum Depression Treatment
Sign Up For More News

FAQ

arrow icon

What is SAGE Therapeutics Inc (SAGE) stock price today?

The current price of SAGE is 0 USD — it has decreased -0.23 % in the last trading day.

arrow icon

What is SAGE Therapeutics Inc (SAGE)'s business?

arrow icon

What is the price predicton of SAGE Stock?

arrow icon

What is SAGE Therapeutics Inc (SAGE)'s revenue for the last quarter?

arrow icon

What is SAGE Therapeutics Inc (SAGE)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for SAGE Therapeutics Inc (SAGE)'s fundamentals?

arrow icon

How many employees does SAGE Therapeutics Inc (SAGE). have?

arrow icon

What is SAGE Therapeutics Inc (SAGE) market cap?